RARITAN, NJ, May 31, 2014 – Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of single-agent ibrutinib (IMBRUVICA®) suggest continued durable responses in patients with treatment-naïve (TN) or relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to data from an analysis that will be discussed in an oral presentation on Tuesday, June 3 at the American Society of Clinical Oncology (ASCO) 50th annual meeting in Chicago, IL. Janssen Research & Development, LLC, announced the results today, which show ibrutinib continued to produce high overall response rates (ORR) (78 percent for all treated patients, with the median duration of response not achieved after almost 30 months). In addition, the rate of Grade 3 or higher adverse events (AEs) or those leading to hospitalization decreased after one year on treatment.
In a separate poster presentation to be discussed today, data suggest the combination of single-agent ibrutinib administered orally once-daily with ofatumumab, a CD20-directed cytolytic monoclonal antibody administered intravenously, is tolerable in patients with previously treated relapsed or refractory CLL/SLL.
Ibrutinib (IMBRUVICA®) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia | Johnson & Johnson
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.